TEC-Pharma
Company
TEC-Pharma develops one asset, preclinical (FE002-Cart in knee chondral defects). Mostly cell therapy.
- 1
- Asset
- Furthest stage
- Preclinical
- 0
- Trials
- 0
- Signals
Pipeline
1Allogeneic chondroprogenitor spheroids engineered to promote functional chondrogenesis and repair cartilage defects.
Preclinical, Cell therapy, knee chondral defects
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Similar companies6